trending Market Intelligence /marketintelligence/en/news-insights/trending/vyrahsww1fnocvnbi3safg2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Johnson & Johnson to expand coverage of joints drug

L.K. Bennett: Bankruptcy Case Study

State Of Singapore Online Video Subscription

Power Forecast Briefing: Capacity Shortfalls to Test the Renewable Energy Transition

Episode 43 - More Change, M&A On Horizon For Equity Research Industry


Johnson & Johnson to expand coverage of joints drug

Janssen Biotech Inc. sought U.S. FDA approval to expand Simponi Aria's coverage as a treatment for active psoriatic arthritis and active ankylosing spondylitis.

The Johnson & Johnson unit filed two supplemental biologics license applications for the drug, which is already approved as a therapy for adult patients with moderate to severe active rheumatoid arthritis.

Psoriatic arthritis and ankylosing spondylitis affect more than 2 million Americans, Johnson & Johnson noted in a news release.

Arthritis is any disorder that affects joints. Ankylosing spondylitis is a form of arthritis.